Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

In association with therapeutic drug monitoring of immunosuppressive drugs,
pharmacogenetics has rapidly emerged as an additional tool to refine dose selection or …

What is known and objectives Tacrolimus (TAC) is a first‐line immunosuppressant which is
used to prevent transplant rejection after solid organ transplantation (SOT). However, it has …

Background Common genetic variants of the enzymes and efflux pump involved in
tacrolimus disposition have been associated with calcineurin inhibitor nephrotoxicity, but …

Aims Tacrolimus (TAC) is one of the most successful immunosuppressive drugs in
transplantation. Its pharmacokinetics (PK) and pharmacogenetics (PG) have been …

Although immunoassays are widely used for therapeutic drug monitoring of various
immunosuppressants, a major limitation of these immunoassays is the significant cross …

Racial differences among kidney transplant recipients may impact the total daily tacrolimus
dose required to achieve therapeutic tacrolimus concentrations. Previous studies suggest …

Background Individual differences in the pharmacokinetics (PK) of tacrolimus (TAC), an
immunosuppressive drug, are reportedly associated with single-nucleotide polymorphisms …

An exploratory, post hoc analysis was performed using data from a prospective, multicenter,
open‐label, randomized, two‐period (14 d per period), two‐sequence, crossover, steady …